Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer.
Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer.
复制标题
吉西他滨和奥沙利铂联合化疗治疗难治性胰腺癌患者。
作者：
Isayama H;Nakai Y;Yamamoto K;Sasaki T;Mizuno S;Yagioka H;Yashima Y;Kawakubo K;Kogure H;Arizumi T,Togawa O;Ito Y;Matsubara S;Yamamoto N;Sasahira N;Hirano K;Tsujino T;Tada M;Omata M;Koike K.
目的：探讨吉西他滨和奥沙利铂联合化疗对难治性胰腺癌的疗效。方法：吉西他滨1, 000 mg/m2+奥沙利铂85 mg/m2+吉西他滨30 min+奥沙利铂120 min，第1天和第15天。每4周重复治疗一次，每2个周期评价肿瘤缓解情况。18名患者（82%）接受二线化疗，4名患者（18%）接受三线化疗。所有病例均未出现肿瘤缓解。13例患者病情稳定，疾病控制率为59%。中位总生存期和进展时间分别为6.8个月（95% CI，2.8-11.5）和2.6个月（95% CI，1.5-3.8）。一线化疗后的中位总生存期为22.7个月（95% CI，14.8-24.4）。主要的3/4级不良事件包括中性粒细胞减少症（14%），厌食症（23%），周围神经病变（14%）。结论吉西他滨和奥沙利铂联合化疗是可以耐受的，但在难治性的晚期胰腺癌患者的活动有限。
ObjectiveThe aim of this study was to investigate the effect of gemcitabine and oxaliplatin combination chemotherapy on refractory pancreatic cancer.MethodsPatients with advanced pancreatic cancer refractory to gemcitabine and S-1 were treated with gemcitabine 1,000 mg/m 2 over 30 min and oxaliplatin 85 mg/m 2 over 120 min on days 1 and 15. Treatment was repeated every 4 weeks and tumor response was assessed every two cycles by RECIST version 1.0.ResultsTwenty-two patients with pathologically confirmed pancreatic cancer were enrolled. The treatment was administered as a second-line chemotherapy in eighteen patients (82%) and as a third-line chemotherapy in four patients (18%). Tumor response did not occur in any of the cases. Thirteen patients demonstrated stable diseases, and the disease control rate was 59%. Median overall survival and time to progression were 6.8 months (95% CI, 2.8–11.5) and 2.6 months (95% CI, 1.5–3.8), respectively. Median overall survival from the first-line chemotherapy was 22.7 months (95% CI, 14.8–24.4). The major grade 3/4 adverse events included neutropenia (14%), anorexia (23%), and peripheral neuropathy (14%).ConclusionsGemcitabine and oxaliplatin combination chemotherapy was tolerable but had limited activity in patients with advanced pancreatic cancer in a refractory setting.